In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Rare disease trials Q&A
A Pharmaceutical Market Europe (PME) Q&A article authored by Gretchen Goller and Valerie Legrand, discussing the challenges of rare disease trials, including those of recruitment and retention unique to rare disease studies. The article also provides insights on solutions to these challenges.
-
ICER's Growing Impact On Drug Pricing And Reimbursement
Read Forbes' original article referencing the ICON whitepaper ‘The Role of ICER as an Independent HTA Organisation’, exploring how ICER may have a greater impact on payer decision-making than expected and can be viewed as a ‘decision resource’ for budgetary and formulary policy decision making.
-
The rise of patient-centricity
In the April 2019 issue of Pharmaceutical Market Europe (PME), p.32-34, Matt McCarty discusses the importance of understanding what patients value and ways to gather patient insights.
-
ICON CIO – Telemedicine, Wearables & AI Could Boost Clinical Trial Participation
A Diginomica article featuring commentary from ICON's Tom O’Leary, discussing the opportunities for technology to overcome key challenges in clinical trials, such as retention and diversity, by making participation less burdensome for patients.
-
Embracing Digital Health
A thought leadership article by Vicki Anastasi, Matt McCarty and Marie McCarthy, published by the Journal of mHealth, on the skills and expertise needed to best use mHealth to transform clinical trials, thereby improving the efficacy of therapies in the real world and increasing pharma R&D productivity.
-
Converging Goals: How a Focus on the Patient Drives Stronger Healthcare Partnerships
The foundation of healthcare is shifting from a provider-based to a patient-centric, or value-based, model. With aging populations, better-informed patients, and emerging technologies, the responsibilities and roles of every stakeholder in this industry is changing. Gain further insights on this topic from ICON expert Vicki Anastasi (VP, Global Head, Medical Device and Diagnostics Research, Real World Evidence Late Phase Research) in this recent MPO Magazine article.
-
How ICON is Using Analytics & Wearables to Enhance Clinical Trials
Read Computer Weekly's recent ICON article to learn how our company is investing in emergent technology to boost the attractiveness of trials as a care option and attract more participants, while enhancing internal efficiency around drug and device development.
-
21st Century Cures Act: Ushering in a New Chapter in the Expanding Use of Real-World Evidence
This article, published in Pharmafocus' April 2019 issue, features expert insights on the 21st Century Cures Act's relation to the expanding use of real-world evidence (RWE), as shared by ICON's Jim Carroll (VP, RWE) and Vicki Anastasi (VP & Global Head, RWE, Late Phase Research).
-
Patients is a Virtue
As patients are increasingly using digital and social media as part of their consumer behaviour, it becomes important for healthcare to also be digitally enabled. In order to truly understand the value of direct patient engagement and advocacy, pharma companies need to take the time to understand how to grow successful, mutually beneficial relationships.
-
Wearables in Virtual Trials
Marie McCarthy shares her insights on how wearables are improving the clinical trial experience for patients and satisfying the need to collect data for real-world use studies, "Connected devices drastically improve trials' patient-centricity, generating endpoints perceived as more valuable having greater value."
